| Name | Title | Contact Details |
|---|
We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.
Marsh is a global leader in insurance broking and risk management. Marsh helps clients succeed by defining, designing, and delivering innovative industry-specific solutions that help them effectively manage risk. Marsh’s approximately 26,000 colleagues work together to serve clients in more than 130 countries. Marsh is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE:MMC), a global professional services firm offering clients advice and solutions in the areas of risk, strategy, and human capital. With 55,000 employees worldwide and annual revenue exceeding $12 billion, Marsh & McLennan Companies is also the parent company of Guy Carpenter, a global leader in providing risk and reinsurance intermediary services; Mercer, a global leader in talent, health, retirement, and investment consulting; and Oliver Wyman, a global leader in management consulting.
Oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies.
NephroGenex is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Canadian Bacterial Diseases Network (CBDN) is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.